Abstract 2254
Background
5-year survival with platinum-based combination chemotherapies in testicular cancer is 95%. Existing prognostic scoring scales may be insufficient to predict which patient will benefit from treatment. Additional prognostic factors should be determined. Unlike left testicular vein, right testicular vein drains to vena cava. Therefore, the systemic spread of the testicular cancers of each side considered to be different due to the difference of vascular structures of the right and left testis. In this study, we aimed to investigate the effects of tumor localization on survival in patients with nonseminomatous testicular cancer.
Methods
We enrolled 321 non-seminomatous testicular cancer patients who followed up at Gulhane Research and Training Hospital in between January 1981, and December 2015. We retrospectively obtained data of demographic features, histopathological results, information of surgical operations and chemo-radiotherapy protocols, history of autologous stem cell transplantation from patients’ files.
Results
We enrolled 321 non-seminomatous testicular carcinoma patients and summarized demographic information and treatment methods in the table. Median age was 34 (18-77) years. The primary tumor was in left testis in 152 (47.2%) patients and in right testis in 170 (52.8%) patients. The most common histopathological diagnosis was mixed non-seminomatous germ cell tumor (39.4%). One hundred forty-six (44.3%) cases were metastatic at the time of diagnosis. Median follow-up period was 88.3 months (1-386). Median 10-year survival rate was 74.1%, and the 20-year survival rate was 70.7%. We examined the effect of primary tumor localization and found that primary tumor localization was significantly different regarding survival between left and right testis (337.6 months vs. NR, p = 0.001). In patients with a right testicular tumor the recurrence rate was significantly higher (84.7% vs. 68.2%; p = 0.002).
Conclusions
The localization of primary testicular tumor (left or right) was statistically significant regarding survival. The effect of tumor localization on survival was independent of the presence of metastasis at the time of diagnosis, histopathological type, site of metastasis, and disease stage.
Clinical trial identification
.
Editorial acknowledgement
Legal entity responsible for the study
Gulhane Education and Research Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract